

Sodium Aescinate Datasheet

5th Edition (Revised in January, 2017)

[Product Information]

Name: Sodium Aescinate

Catalog No.: CFN99509

Cas No.: 20977-05-3


Purity: > 98%

M.F: C₅₄H₈₄NaO₂₃

M.W: 1153.20

Physical Description: White powder

Synonyms: Butanoic acid,3-(acetyloxy)-2-methyl-, (5xi,8xi,9xi,10xi,16alpha,17xi,18xi,21beta)-16,21-epoxy-3-[[O-alpha-D-glucopyranosyl-(1->4)-O-[beta-D-xylopyranosyl-(1->2)]-beta-D-glucopyranuronosyl]oxy]-22,24-dihydroxyolean-12-en-28-yl ester, monosodium salt(3,4,5-triol).



[Intended Use]

1. Reference standards;
2. Pharmacological research;
3. Food research;
4. Synthetic precursor compounds;
5. Intermediates & Fine Chemicals;
6. Others.

[Source]

The herbs of *Aesculus hippocastanum L.*

[Biological Activity or Inhibitors]

Sodium aescinate can protect the ischemia brain on reperfusion injury, via increasing Bcl-2 protein expression and decreasing Caspase-3 protein expression.^[1]

Sodium aescinate has obvious antiangiogenic effect, the initiation of angiogenesis and proliferation of endothelial cell are inhibited and the secretion of VEGF is also decreased.^[2]

Sodium aescinate has immunity enhancing and antioxidative effects, sodium aescinate injection liquid can decrease oxidative injury and enhance immunity functions in hepatocellular carcinoma (HCC) mice. ^[3]

Sodium aescinate may lessen and (or) delay the genesis of brain edema induced by intracerebral hemorrhage, and improve the prognosis.^[4]

Sodium aescinate can protect against liver injury induced by methyl parathion and that the mechanism of action is related to its antioxidative and anti-inflammatory effects.^[5]

[Solvent]

Pyridine, Methanol, Ethanol, etc.

[HPLC Method]^[6]

Mobile phase: Phosphoric acid solution-Acelonitrile=56:44 ;

Flow rate: 1.0 ml/min;

Column temperature:Room Temperature;

The wave length of determination: 220 nm.

[Storage]

2-8°C, Protected from air and light, refrigerate or freeze.

[References]

- [1] Fan X J, Guo K, Xiao B, *et al.* *Zhong nan da xue xue bao. Yi xue ban*, 2005, 30(3): 261-5, 275.
- [2] Zhao B Z, Yang X R, Wei G, *et al.* *Chinese Journal of New Drugs*, 2007, 16(17):1357-60.
- [3] Wang Y K, Han J, Xiong W J, *et al.* *Molecules*. 2012,17(9):10267-75.
- [4] Xie X L, Liu Y H, Xue Y X. *Chinese Pharmacological Bulletin*, 2007, 23(2):173-7.
- [5] Du Y, Wang T, Jiang N, *et al.* *Exp. Ther. Med.*, 2012, 3(5):818-22.
- [6] Zhang W, Zhai G, Liu L, *et al.* *Chinese Journal of Pharmaceutical Analysis*, 2008, 28(1):104-7.

[Contact]

Address:

S5-3 Building, No. 111, Dongfeng Rd.,
Wuhan Economic and Technological Development Zone,
Wuhan, Hubei 430056,
China

Email: info@chemfaces.com

Tel: +86-27-84237783

Fax: +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com